DOI: https://doi.org/10.22141/2224-0713.1.95.2018.127414

The use of amantadine in Parkinson’s disease, parkinsonism and complications of levodopa therapy

I.N. Karaban

Abstract


The article presents a scientific review of current views on the role of glutamate (NMDA) receptor blockers in the pathogenesis and treatment of Parkinson’s disease, parkinsonian syndromes and dyskinetic disorders as complications of levodopa therapy. The greatest attention is paid to the mechanism of action, possibilities and advantages of using amantadine.

Keywords


Parkinson’s disease; parkinsonism; levodopa-induced dyskinesias; amantadine

References


Иллариошкин С.Н., Федотова Е.Ю., Селиверстов Ю.А. Современные высокотехнологичные методы лечения болезни Паркинсона // Болезни мозга: медицинские и социальные аспекты / Под ред. Е.И. Гусева, А.Б. Гехт. — М.: Буки-Веди, 2016. —

С. 543-552.

Карабань И.Н. Применение блокатора глутаматных рецепторов амантадина в неврологии // Международный неврологический журнал. — 2012. — № 2 (48). — С. 195-201.

Крыжановский Г.Н., Карабань И.Н., Магаева С.В., Кучеряну В.Г., Карабань Н.В. Болезнь Паркинсона. — М.: Медицина, 2002. — 336 с.

Левин О.С., Федорова Н.В. Болезнь Паркинсона. — М.: Медпрессинформ, 2017. — 315 с.

Румянцева С.А., Беневольская Н.Г. Новые направления в патогенетической терапии инсульта // Атмосфера. Нервные болезни: журнал для практических врачей. — 2006. — № 4. — С. 29-34.

Федорова Н.В., Ветохина Т.Н. Диагностика и лечение нейролептических экстрапирамидных синдромов: Учебно-методическое пособие. — М.: РАМПО, 2006. — 36 с.

Aarsland D., Ballard C., Walker Z. Memantine in patients with Parkinson’s disease, dementia or dementia with Lewy bodies // Lancet Neurol. — 2009. — V. 8. — P. 613-618.

Ahmed I., Bose S.K., Pavese N., Ramlackhansingh A., Turkheimer F., Hotton G., Hammers A., Brooks D.J. Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias // Brain. — 2011. — 134 (Pt. 4). — 979-986.

Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopainduced dyskinesia: potential for new therapies // Nat. Rev. Neurosci. — 2001. — 2. — 577-588.

Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopainduced dyskinesias in parkinsonian monkeys // Mov. Disord. —

— 13. — 798-802.

Caumont A.S., Octave J.N., Hermans E. Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells // Neurosci Lett. — 2006. — 394. —

-201.

Cersósimo M.G., Micheli F.E. Antiglutamatergic drugs in the treatment of Parkinson’s disease / Koller C., Melamed E., editors // Handbook of clinical neurology. V. 84: Parkinson’s disease and related disorders. Part II. — N.Y.: Elsevier, 2007. — Р. 127-136.

Chase T.N., Bibbiani F., Oh J.D. Striatal glutamatergic mecha­nisms and extrapyramidal movement disorders // Neurotox. Res. — 2003. — 5 (1–2). — 139-146.

Chase T.N., Engber T.M., Mouradian M.M. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson’s disease // Adv. Neurol. —

— 69. — 497-501.

Crosby N.J., Deane K.H., Clarke C.E. Amantadine for dyskinesia in Parkinson’s disease // Cochrane Database Syst. Rev. — 2003. —

— CD003467.

Da Silva-Junior F.P., Braga-Neto P., Sueli Monte F.,

De Bruin V.M. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study // Parkinsonism Relat. Disord. — 2005. — 11. — 449-452.

Elahi B., Phielipp N., Chen R. N-methyl-D-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis // Can. J. Neurol. Sci. — 2012. — 39. — 465-472.

Halliday G. The progression of pathology in Parkinson’s dise­ase // Ann. N.Y. Acad. Sci. — 2010. — V. 1184. — Р. 188-195.

Ilzenberg R., Bonuccelli U., Schechtman E., Miniowich A., Strugatsky R., Ceravolo R., Logi C., Rossi C., Klein C., Rabey J.M. Association between amantadine and the onset of dementia in Parkinson’s disease // Mov. Disord. — 2006. — 21. — 1375-1379.

Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations // Mov. Disord. — 2005. —

(Suppl. 11). — S11-S16.

Jankovic J., Stacy M. Medical management of levodopa-­associated motor complications in patients with Parkinson’s disease //CNS Drugs. — 2007. — 21. — 677-692.

Kaplan N., Vituri A., Korczyn A.D., Cohen O.S., Inzelberg R., Yahalom G., Kozlova E., Milgrom R., Laitman Y, Friedman E., Rosset S., Hassin-Baer S. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson’s disease // J. Mol. Neurosci. — 2014. — 53. — 183-188.

Luginger E., Wenning G.K., Boesch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease // Mov. Disord. — 2000. — 15. — 873-878.

Melki R. Role of different alpha-synuclein strains in synucleinopa-thies, similarities with other neurodegenerative diseases //

J. Parkinsons Dis. — 2015. — 5 (2). — 217-227.

Metman L.V., DelDotto P., LePoole K. et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study // Arch. Neurol. — 1999. — 56. — 1383-1386.

Merello M., Perez-Lloret S., Antico J., Obeso J.A. Dyskinesias induced by subthalamotomy in Parkinson’s disease are unresponsive to amantadine // J. Neurol. Neurosurg. Psychiatry. — 2006. — 77 (2). — 172-174.

Nutt J.G., Chung K.A., Holford N.H. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study // Neurology. — 2010. — V. 74 (15). — 1191-1197.

Olanow C.W. The scientific basis for the current treatment of Parkinson’s disease // Annu Rev. Med. — 2004. — 55. — 41-60.

Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson’s disease // Neurology. — 2009. — V. 72, 21 (Suppl. 4). — Р. 149.

Ossola B., Schendzielorz N., Chen S.H., Bird G.S., Tuominen R.K., Männistö P.T., Hong J.S. Amantadine protects dopamine neurons by a dual action. — reducing activation of microglia and inducing expression of GNDF in astroglia // Neuropharmacology. — 2011. — 61 (4). — 574-582.

Pahwa R., Tanner C.M., Hauser R.A., Sethi K., Isaacson S., Truong D., Struck L., Ruby A.E., McClure N.L., Went G.T., Stempi­en M.J. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study) // Mov. Disord. — 2015. — 30 (6). — 788-795.

Roman A., Rogoz Z., Kubera M. et al. Concominent administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test // Pharmacol. Rep. — 2009. — 61. — 1069-1077.

Sawada H., Oeda T., Kuno S. et al. Amantadine Study Group. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial // PloS One. — 2010. — 5 (12). — e 15298.

Stocchi F., Rascol O., Destee A., Hattori N., Hauser R.A., Lang A.E., Poewe W., Stacy M., Tolosa E., Gao H., Nagel J., Merschhemke M., Graf A., Kenney C., Trenkwalder C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia. — 13-week, randomized, dose-finding study // Mov. Disord. — 2013. — 28 (13). — 1838-1846.

Thomas A., lacono D., Luciano A.L., Armellino K., Di lorio A.,

Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease // J. Neurol. Neurosurg. Psychiatry. — 2004. — 75. — 141-143.

Uitti R.J., Rajput A.H., Ahlskog J.E., Offord K.P., Schroeder D.R., Ho M.M., Prasad M., Rajput A., Basran P. Amantadine treatment as an independent predictor of improved survival in Parkinson’s disease // Neurology. — 1996. — 46. — 1551-1556.

Verhagen Metman L., Morris M.J., Farmer C., Gillespie M., Mosby K., Wuu J., Chase T.N. Huntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadine // Neuro­logy. — 2002. — 59. — 694-699.

Wolf E., Seppi K., Katzenschlager R., Hochschorner G., Rans-mayr G., Schwingenschuh P., Ott E., Kloiber I., Haubenberger D., Auff E., Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease // Mov. Disord. — 2010. — 25. — 1357-1363.




Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта